Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nitric oxide–cyclic guanosine monophosphate–ATP-sensitive potassium channel (NO–cGMP–KATP) pathway is a fundamental signaling cascade that regulates vascular tone, pain transmission, and cellular protection [1.3.1]. It begins with the production of nitric oxide (NO), which activates soluble guanylyl cyclase (sGC) to produce the second messenger cyclic guanosine monophosphate (cGMP) [1.2.2, 1.3.3]. Elevated cGMP levels activate protein kinase G (PKG), which subsequently triggers the opening of ATP-sensitive potassium (KATP) channels [1.2.2, 1.3.2]. The resulting efflux of potassium ions causes cell membrane hyperpolarization, leading to smooth muscle relaxation in blood vessels and decreased excitability in sensory neurons [1.2.1, 1.3.1]. This pathway is a critical mediator of the effects of various drugs, including vasodilators like nitroglycerin and analgesics like diclofenac [1.1.2, 1.2.1, 1.2.5]. Dysregulation of this signaling cascade is implicated in several pathological conditions, such as hypertension, erectile dysfunction, and chronic pain [1.2.2, 1.3.1]. Pharmacological modulation of the pathway can be achieved through NO donors, sGC stimulators, phosphodiesterase inhibitors, or KATP channel openers [1.1.3, 1.2.4, 1.3.2]. However, therapeutic use of these agents requires careful management due to potential side effects like hypotension and headache [1.1.3, 1.3.1]. Overall, the NO–cGMP–KATP pathway represents a versatile therapeutic target for managing cardiovascular and neurological disorders.
Activation of the pathway involves NO-mediated stimulation of soluble guanylyl cyclase, increasing cGMP levels, which activates protein kinase G (PKG). PKG then promotes the opening of ATP-sensitive potassium (KATP) channels, leading to potassium efflux and membrane hyperpolarization.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nitric oxide–cyclic guanosine monophosphate–ATP-sensitive potassium channel pathway (NO–cGMP–KATP pathway) (NO–cGMP–KATP pathway).